Modality
mRNA
MOA
EGFRi
Target
SHP2
Pathway
RNA Splicing
UCCeliac
Development Pipeline
Preclinical
~Aug 2022
→ ~Nov 2023
Phase 1
~Feb 2024
→ ~May 2025
Phase 2
Aug 2025
→ Feb 2027
Phase 2Current
NCT08009787
1,099 pts·UC
2025-08→2027-02·Completed
1,099 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-02-0510mo awayPh2 Data· UC
Trial Timeline
Q42026Q2Q3Q42027
P2
Complet…
Catalysts
Ph2 Data
2027-02-05 · 10mo away
UC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08009787 | Phase 2 | UC | Completed | 1099 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |